期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CYP2C19基因多态性及其对质子泵抑制剂疗效影响研究进展 被引量：24

Advances in CYP2C19 genetic polymorphism and its impact on efficacy of PPI
原文传递
导出
摘要 质子泵抑制剂(PPI)是目前临床上治疗酸相关性疾病的首选药物。但其疗效存在个体差异,且其对老年人和肝肾功能不全患者的安全性也倍受关注。这些问题都与患者CYP2C19基因多态性有密切关系。本文对CYP2C19基因多态性及其对PPI的药动学、药效学和临床疗效的影响作一综述,并对临床合理应用PPI作进一步探讨。 Proton pump inhibitors （PPI） are the drugs of first choice for the treatment of acid-related diseases. But there are individual differences in the efficacy, and their safety in older people and patients with liver and kidney dysfunction also have been widely noticed. These issues are closely related to the CYP2C19 genetic polymorphism. The paper reviewed the genetic polymorphism of CYP2C19 and its effect on the pharmacokinetics, pharmacodynamics and clinical efficacy of PPI, and the clinical application of PPI was further studied.
作者 李小雯 郑松柏
机构地区 复旦大学附属华东医院消化科
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2013年第10期775-779,共5页 Chinese Journal of New Drugs and Clinical Remedies
关键词 质子泵抑制剂 细胞色素C类 基因型 基因多态性 研究 proton pump inhibitors cytochromes c genotype genetic polymorphism research
分类号 R975 [医药卫生—药品]
  • 相关文献

参考文献37

  • 1GOLDSTEIN JA. Clinical relevance of genetic polymorphisms inthe human CYP2C subfamily[J]. Br J Clin Pharmacol, 2001, 52(4): 349-355.
  • 2LI-WAN-PO A, GIRARD T,FARNDON P, et al. Pharmaco-genetics of CYP2C19 : functional and clinical implications of anew variant CYP2C19*17[J]. Br J Clin Pharmacol, 2010, 69(3):222-230.
  • 3PINTO N, DOLAN ME. Clinically relevant genetic variations indrug metabolizing enzymes[J]. Curr Drug Metab, 2011, 12(5):487-497.
  • 4de MORAIS SM, WILKINSON GR, BLAISDELL J, et al. Themajor genetic defect responsible for the polymorphism of S -mephenytoin metabolism in humans[J]. J Biol Chem, 1994, 269(22): 15419-15422.
  • 5de MORAIS SM, WILKINSON GR, BLAISDELL J,et al.Identification of a new genetic defect responsible for thepolymorphism of (S) - mephenytoin metabolism in Japanese [J].Mol Pharmacol, 1994,46(4): 594-598.
  • 6BRAVO-VILLALTA HV, YAMAMOTO K, NAKAMURA K, etal. Genetic polymorphism of CYP2C9 and CYP2C19 in aBolivian population : an investigative and comparative study [J].Eur J Clin Pharmacol, 2005, 61(3): 179-184.
  • 7GOLDSTEIN JA, ISHIZAKI T, CHIBA K, et al. Frequencies ofthe defective CYP2C19 alleles responsible for the mephenytoinpoor metabolizer phenotype in various Oriental, Caucasian,Saudi Arabian and American black populations [J]. Pharmacoge -netics, 1997, 7(1): 59-64.
  • 8SIM SC, RISINGER C, DAHL ML,et d. A common novelCYP2C19 gene variant causes ultrarapid drug metabolismrelevant for the drug response to proton pump inhibitors andantidepressants[J]. Clin Pharmacol Ther, 2006,79(1): 103-113.
  • 9RUDBERG I, MOHEBI B, HERMANN M, et al. Impact of theultrarapid CYP2C19*17 allele on serum concentration ofescitalopram in psychiatric patients [J]. Clin Pharmacol Ther,2008, 83(2): 322-327.
  • 10HAGYMASI K, MULLNER K, HERSZfiNYI L, et al. Updateon the pharmacogenomics of proton pump inhibitors [J], Pharma -cogenomics, 2011, 12(6) : 873-888.

二级参考文献12

  • 1Internationgal Agency for Research on Cancer, World Health Organization. Infection with Helicobacter pylori. In Schistosomes, liver flukes and Helicobacter pylori. IARC Lyon, 1994, 177-202.
  • 2Kawabata H, Habu Y, Tomioka H, et aI. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxieillin and clarithromycin. Aliment Pharmacol Ther, 2003, 17:259-264.
  • 3Egan LJ, Myhre GM, Mays DC, et al. CYP2C19 pharmacoge netics in the clinical use of proton pump inhibitors for gastro- oesophageal reflux disease:variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment-Pharmacol Ther, 2003, 17:1521-1528.
  • 4Barbara GS, Joanna W, Teresa S, et al. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid related disorders with Helieobaeter. pylori infection. Eur J Clin Pharmacol, 2005, 61: 375-379.
  • 5Wrighton SA, Stevens JC, Becker GW, et al. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'hydroxylation. Arch Biochem Biophys, 1993, 306: 240-245.
  • 6De Morals SMF, Wiekimon GR, Blaidell J, et al. The maior genetic defect responsible for the polymorphism of S mephenytoin in human. JBiolChem, 1994, 269:15149-15422.
  • 7De Morals SMF, Wickimon GR, Blaidell J, et al. Identifieation oi" a new genetic defect responsible for the polymorphism of S mephenytoin metabolism in Japanese. Mol Phammcol, 1994, 46, 594-598.
  • 8Goldstein N, Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Haarmacol, 2001, 52 : 349-356.
  • 9Malfer heiner P, Megraud, Morain C, et al. Current conceptionthe management of Helicobacter pylori infection:the Maastricht Consensus Report. Gut, 2007, 56: 772-781.
  • 10Fischbach L, Evans EL. Meta analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first line therapies for Helicobacter pylori. Aliment Pharmacol Ther, 2007, 26: 343-357.

共引文献15

同被引文献251

引证文献24

二级引证文献293

中国新药与临床杂志
2013年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部